Growth Metrics

Halozyme Therapeutics (HALO) Short-term Investments (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Short-term Investments for 13 consecutive years, with $9.0 million as the latest value for Q4 2025.

  • Quarterly Short-term Investments fell 98.13% to $9.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.0 million through Dec 2025, down 98.13% year-over-year, with the annual reading at $9.0 million for FY2025, 98.13% down from the prior year.
  • Short-term Investments for Q4 2025 was $9.0 million at Halozyme Therapeutics, down from $282.3 million in the prior quarter.
  • The five-year high for Short-term Investments was $668.3 million in Q1 2022, with the low at $9.0 million in Q4 2025.
  • Average Short-term Investments over 5 years is $313.4 million, with a median of $290.6 million recorded in 2024.
  • The sharpest move saw Short-term Investments surged 182.42% in 2021, then crashed 98.13% in 2025.
  • Over 5 years, Short-term Investments stood at $622.2 million in 2021, then tumbled by 79.33% to $128.6 million in 2022, then surged by 69.23% to $217.6 million in 2023, then skyrocketed by 120.66% to $480.2 million in 2024, then plummeted by 98.13% to $9.0 million in 2025.
  • According to Business Quant data, Short-term Investments over the past three periods came in at $9.0 million, $282.3 million, and $486.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.